About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Cancer Drug 'Nilotinib' Shows Promise Against Parkinson's

by Bidita Debnath on October 19, 2015 at 11:27 PM
Font : A-A+

 Cancer Drug 'Nilotinib' Shows Promise Against Parkinson's

A preliminary research presented at a US medical conference suggests that cancer drug may be helpful in improving memory and motor skills in patients with Parkinson's disease. The trial at Georgetown University involved 12 people who had Parkinson's or a related condition called Lewy body dementia.

All 11 who completed the trial using the drug nilotinib -- marketed by Novartis as Tasigna, which has been approved by the US Food and Drug Administration for leukemia -- showed improvements in movement and mental function by the end of the study, according to the findings presented at the Society for Neuroscience meeting in Chicago.

Advertisement

For some, the gains were dramatic, particularly those who were treated early in the course of their disease. One person who had been confined to a wheelchair was able to walk again, researchers said. Three others regained their ability to speak and hold conversations.

"To my knowledge, this study represents the first time a therapy appears to reverse -- to a greater or lesser degree depending on stage of disease -- cognitive and motor decline in patients with these neurodegenerative disorders," said a statement by researcher Fernando Pagan, a Georgetown University associate professor of neurology.
Advertisement

"But it is critical to conduct larger and more comprehensive studies before determining the drug's true impact." The drug appears to work by clearing toxic proteins in the brain. Patients were given nilotinib, a treatment for chronic myelogenous leukemia (CML), in escalating doses of 150 to 300 milligrams over the course of six months.

The doses used were much smaller than the amount used to treat cancer -- which is up to 800 mg daily -- and patients experienced no major side effects. The study was designed to test safety, and did not compare the drug to other treatments or to a placebo.

The drug is costly, however. The 800 mg daily dose used for cancer treatment costs $10,360 per month, according to the researchers. Larger clinical trials with nilotinib for patients with Parkinson's and Alzheimer's could begin as early as 2016.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
Test Your Knowledge on Sugar Intake and Oral Health
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Oncology Drug Delivery Systems Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment 

Most Popular on Medindia

Indian Medical Journals Post-Nasal Drip How to Reduce School Bag Weight - Simple Tips Accident and Trauma Care Hearing Loss Calculator Sinopril (2mg) (Lacidipine) Daily Calorie Requirements Selfie Addiction Calculator Vent Forte (Theophylline) Find a Hospital
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Cancer Drug 'Nilotinib' Shows Promise Against Parkinson's Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests